N/A N=60 Predicting Placental Pathologies by Ultrasound Imaging
Intrauterine Growth Restriction · Villitis · IUGR
Primary: Number of Participants With Uterine Artery Indices Completed — 13; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=91 Saizen in Intra-uterine Growth Retardation
Children Born With Serious Intra-uterine Growth Retardation
Primary: Final Height — 145.90; 150.06; 153.27; 155.59 cm
N/A N=5 Randomized Clinical Trial: Expectant Management vs Laser Treatment of Monochorionic Twins With Severe Selective Intrauterine Growth Retardation and Absent or Reverse Diastolic Flow in the Umbilical Artery
Intrauterine Growth Retardation
Primary: Survival — 100; 100 percentage of AGA babies who survived
N/A N=3,188 Low-birthweight Infant Feeding Exploration
Low Birthweight · Pre-Term
Primary: Length-for-Age Z-score — -1.43 Z-score
Phase 3 N=208 Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation
Growth Disorders · Intrauterine Growth Retardation
Primary: Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm — 3.07; 3.97; 2.84 cm/year — p=0.02922
N/A N=813 Third Trimester Screening of Fetal Growth Restriction
Fetal Growth Retardation · Fetal; Slow Growth
Primary: Rate of Small for Gestational Age at Birth Identified Antenatally — 28; 46 Participants
Phase 4 N=90 Physiologic Approach to Sodium Supplementation in Premature Infants
Postnatal Growth Disorder
Primary: Change in Somatic Growth (Weight) — 0.04; 0.16 score on a scale — p=0.162
Phase 2 N=121 IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
Retinopathy of Prematurity (ROP)
Primary: Severity of Retinopathy of Prematurity (ROP) as Compared to the Severity of ROP in an Untreated Control Population — 14; 24; 4; 4 participants — p=0.0642
Early Phase 1 N=3 Placental Lesions in Fetal Growth Restrictions
Fetal Growth Retardation
Primary: Number of Participants for Which Intervillous Placental Blood is Detected — 3 Participants
Phase 3 N=136 Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency
Growth Disorders · Insulin-Like Growth Factor-1 Deficiency
Primary: Height Velocity During the First Year - Intent to Treat (ITT)Population — 5.2; 6.9; 7.7 cm/yr — p=<0.0001
N/A N=206 Determination of Abnormal Fetal Growth or Amniotic Fluid With Third Trimester Ultrasounds in Uncomplicated Pregnancies: A Randomized Trial
Uncomplicated Pregnancy · Abnormal Fetal Growth or Fluid
Primary: Number of Participants With Fetal Growth Restriction — 2; 8 Participants
Phase 3 N=46 Growth Retardation In Children With Special Pathological Conditions Or Disease
Endocrine System Diseases
Primary: Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Intent-to-Treat (ITT) Population — -1.29; 2.36 SDS
N/A N=605 Umbilical Cord Milking in Non-Vigorous Infants Developmental Followup (MINVIFU)
Neurodevelopmental Abnormality
Primary: Total and Domain Scores on the Ages and Stages Questionnaire, Third Edition. — 55; 55; 60; 60 score on a scale — p=0.87
N/A N=366 Incubator Weaning of Moderately Preterm Infants
Infant, Newborn · Infant, Moderate Preterm
Primary: Length of Hospital Stay (LOS) From Birth to Discharge (up to 120 Days) — 43; 41 days
N/A N=168 Neurodevelopmental and Growth Outcomes of Early, Aggressive Protein Intake in Very Low Birthweight Infants
Prematurity
Primary: Number of Participants With Weight<10th Percentile for Age — 32; 41 Participants
Phase 3 N=92 Long-Term Treatment With rhIGF-1 in GHIS
Growth Hormone Insensitivity Syndrome
Primary: Annualized Height Velocity Up to 12 Years — 2.6; 8.0; 5.9; 5.5 centimeter per year (cm/y)
N/A N=120 Optimizing Individual Nutrition in Preterm Very Low Birth Weight Infants
Infant, Premature, Diseases · Infant, Small for Gestational Age
Primary: Growth Velocity — 13; 13.1 g kg-1 day-1
N/A N=47 Antecedents of Obesity: Fetal Measures of Adiposity
Obesity
Primary: Infant Adiposity at 24-72 Hours Following Birth — 11 Percentage of total body weight
Phase 1 N=22 PED NEONAT 20-000599 Fetal Body Composition
IUGR · Gestational Diabetes · Pregnancy Related
Primary: Maternal Visceral Adipose Tissue Volume — 97593; 169626; 96787 mm3
N/A N=200 Postoperative Intermittent Intrauterine Balloon Dilatation Therapy.
Intrauterine Adhesion
Primary: Number of Participants With Adhesion Reformation (American Fertility Society Score of Greater Than 0) 8 Weeks Later After the Index Surgery — 21; 38 Participants — p=0.012
Phase 2 N=7 IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency
Short Stature
Primary: Height Velocity — 3.0; 4.3; 6.2; 4.8 cm/y
N/A N=30 Intra-Abdominal Hypertension in Neonatal Intensive Care Patients
Intra-Abdominal Hypertension
Primary: Intra-abdominal Pressure(IAP) Measurements in NICU Patients. — 1219 IAP measurements
Phase 3 N=43 Genotropin Treatment In Very Young Children Born Small For Gestational Age
Infant, Small for Gestational Age
Primary: Change From Baseline in Height Standard Deviation Score (SDS) at Month 24. — 1.63; 0.43 SDS — p=<0.001
Phase 3 N=1 CEUS Evaluation of Hypoxic Ischemic Injury
Hypoxic-Ischemic Encephalopathy · Brain Ischemia Hypoxia
Primary: Detection of Brain Perfusion Abnormalities Using Contrast-enhanced Ultrasound — 1; 0 Participants
N/A N=482 Special Investigation Of Genotropin Long Follow-Up For Patients With A Small For Gestational Age "Scoped for Japanese"
Small for Gestational Age (SGA)
Primary: Number of Participants With Adverse Drug Reaction (ADR) — 24; 4 Participants
Phase 3 N=98 Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)
Foetal Growth Problem · Small for Gestational Age
Primary: Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 260 - Subjects Received NN220 Treatment for 5 Years — -2.9488; -2.9047; 1.2066; 2.0247…
Phase 3 N=45 Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
Insulin-Like Growth Factor-1 Deficiency · Growth Disorders
Primary: Height Velocity From Pretreatment (Week 0) to Week 34 — 7.0 centimeters per year (cm/yr)
Phase 2 N=33 Somatropin Therapy In Children Born Preterm But Appropriate For Gestational Age
Growth Hormone Therapy · Infant, Very Low Birth Weight
Primary: Change in Height Standard Deviation Score (SDS) After 1 Year — 1.099; 0.108 centimeters — p=<0.001
Phase 3 N=22 Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age
Small Gestational Age (SGA)
Primary: Height Velocity — 6.40; 4.40 centimeter (cm)/year — p=0.001
N/A N=480 Maternal Lifestyle and Neonatal Hypoglycemia
Hyperinsulinemia · Miscarriages · Pregnancy
Primary: Neonatal Hypoglycemia — 3; 15 neonates